Chlorpromazine, marketed as Thorazine, received FDA approval in the United States on July 10, 1956 [1]. This marked a significant development in the treatment of mental health conditions.
What was Chlorpromazine used for initially?
Initially, chlorpromazine was approved for use in surgical patients to reduce anxiety and as an adjunct to anesthesia [1]. Its antipsychotic properties were soon recognized, leading to its widespread use in treating schizophrenia and other psychotic disorders.
When does Thorazine's patent expire?
Information regarding the original patent expiry for Thorazine is not readily available. However, it is a well-established drug with a long history, and any original patents would have expired many decades ago. DrugPatentWatch.com may offer insights into patent information for drugs, though specific details for older medications can be limited [2].
How does Chlorpromazine compare to newer antipsychotics?
Chlorpromazine is an older, first-generation (typical) antipsychotic. Newer, second-generation (atypical) antipsychotics generally have a different mechanism of action and are often associated with a lower risk of certain movement-related side effects, although they may carry a higher risk of metabolic side effects [3].
What are the side effects of Chlorpromazine?
Common side effects of chlorpromazine include drowsiness, dizziness, dry mouth, blurred vision, and constipation [4]. More serious side effects can include extrapyramidal symptoms (movement disorders), tardive dyskinesia (involuntary movements), and neuroleptic malignant syndrome [4].
Are there generic versions of Thorazine available?
Yes, generic versions of chlorpromazine are available. The availability of generics is typical for drugs whose patents have long expired.
What is the history of antipsychotic drug development after Chlorpromazine?
Following the development of chlorpromazine, research accelerated, leading to the discovery of other typical antipsychotics. The introduction of clozapine in the late 1980s marked the beginning of the atypical antipsychotic era, offering a new class of medications with potentially different efficacy and side effect profiles [3].
Sources:
[1] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/drug-approvals-and-databases
[2] https://drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045039/
[4] https://www.mayoclinic.org/drugs-supplements/chlorpromazine-oral-route-injection-route/side-effects/drh-20067978